CN116196472B - 一种双导电载药复合神经导管及其制备方法 - Google Patents
一种双导电载药复合神经导管及其制备方法 Download PDFInfo
- Publication number
- CN116196472B CN116196472B CN202310179060.3A CN202310179060A CN116196472B CN 116196472 B CN116196472 B CN 116196472B CN 202310179060 A CN202310179060 A CN 202310179060A CN 116196472 B CN116196472 B CN 116196472B
- Authority
- CN
- China
- Prior art keywords
- conductive
- drug
- concentration
- conduit
- nerve conduit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000005036 nerve Anatomy 0.000 title claims abstract description 77
- 239000002131 composite material Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 23
- 239000003814 drug Substances 0.000 title claims description 18
- 229940079593 drug Drugs 0.000 title claims description 16
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 48
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 40
- 239000004626 polylactic acid Substances 0.000 claims abstract description 40
- 239000000835 fiber Substances 0.000 claims abstract description 38
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims abstract description 34
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims abstract description 34
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims abstract description 34
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229940100243 oleanolic acid Drugs 0.000 claims abstract description 34
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims abstract description 34
- MTPVUVINMAGMJL-UHFFFAOYSA-N trimethyl(1,1,2,2,2-pentafluoroethyl)silane Chemical compound C[Si](C)(C)C(F)(F)C(F)(F)F MTPVUVINMAGMJL-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000126 substance Substances 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 41
- 238000009987 spinning Methods 0.000 claims description 32
- 229920000128 polypyrrole Polymers 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 17
- 238000005507 spraying Methods 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 239000004020 conductor Substances 0.000 claims description 9
- 238000005520 cutting process Methods 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 230000009977 dual effect Effects 0.000 claims 2
- 238000001523 electrospinning Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000008929 regeneration Effects 0.000 abstract description 11
- 238000011069 regeneration method Methods 0.000 abstract description 11
- 210000002569 neuron Anatomy 0.000 abstract description 8
- 230000008439 repair process Effects 0.000 abstract description 6
- 210000003050 axon Anatomy 0.000 abstract description 4
- 230000002688 persistence Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 239000010410 layer Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 13
- 210000002540 macrophage Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000010886 Peripheral nerve injury Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 210000000578 peripheral nerve Anatomy 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000004804 winding Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000795633 Olea <sea slug> Species 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000007590 electrostatic spraying Methods 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MIMUSZHMZBJBPO-UHFFFAOYSA-N 6-methoxy-8-nitroquinoline Chemical compound N1=CC=CC2=CC(OC)=CC([N+]([O-])=O)=C21 MIMUSZHMZBJBPO-UHFFFAOYSA-N 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- UQZIWOQVLUASCR-UHFFFAOYSA-N alumane;titanium Chemical compound [AlH3].[Ti] UQZIWOQVLUASCR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000003486 chemical etching Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- -1 triterpene compound Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0015—Electro-spinning characterised by the initial state of the material
- D01D5/003—Electro-spinning characterised by the initial state of the material the material being a polymer solution or dispersion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0061—Electro-spinning characterised by the electro-spinning apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- General Health & Medical Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Textile Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种双导电载药复合神经导管，该导管为中空管状结构，导管内层为含有导电物质二维碳化钛的聚乳酸静电纺丝纤维；导管外层为导电物质聚吡咯涂层，导管中间层为含齐墩果的聚乳酸静电纺丝纤维，本发明实现了导电的持续性，通过齐墩果酸的缓慢释放进一步促进受损神经元的修复及其轴突的再生，在神经修复治疗中具有很好的应用前景。
Description
技术领域
本发明涉及一种周围神经修复生物材料，具体涉及一种双导电载药复合神经导管及其制备方法。
背景技术
周围神经损伤是由各种原因引起的受该神经支配的区域无法接收近端神经的调控，从而造成相应的功能障碍。目前，自体神经移植是治疗的金标准，但是存在神经供体的来源有限，供体不足和手术时间过长等问题。导电神经导管是人工制成的用以桥接神经断端的组织工程管状物，研究人员发现，电刺激可促进神经突生长、神经元迁移、神经再生和部分早期功能恢复，此外，电刺激还可增强神经再生过程中轴突再生的速度和方向。
二维过渡金属碳氮化物(MXene)是一种二维层状纳米材料,一般是通过化学刻蚀的方法将三元层状化合物MAX相中的A层选择性刻蚀掉作为一种新型二维材料，二维碳化钛作为其中一种，拥有接近金属的电导性。二维碳化钛除了具备石墨烯等传统二维材料的性能外，还同时具有良好的亲水性以及表面官能团(-F、-OH、-О等)可调控性。
聚吡咯由单体吡咯通过电化学法或化学氧化聚合法聚合得到合成。原始状态的聚吡咯是不导电的，但是经过掺杂后，聚吡咯的电导率可急剧上升。聚吡咯在具有良好的导电性的同时，还具有极佳的化学稳定性。体外和体内实验表明，聚吡咯同细胞和组织都具有相当出色的生物相容性,并且在体内长时间植入时不会对机体产生明显的损伤，是一种十分有潜力的组织工程支架材料。
齐墩果酸是一种普遍存在的天然五环三萜化合物，广泛存在于食用水果、蔬菜和药用植物中。近年来，齐墩果酸在治疗治疗支气管炎、肺炎、急性扁桃体炎、牙周炎、菌痢、急性肠胃炎、泌尿***感染等抗击炎症方面取得一定进展，但并未发现其应用于周围神经炎症的报导。
静电纺丝是一种适用于多种聚合物的通用技术，静电纺丝法制备的静电纺丝纤维支架可以从成分和结构上实现对天然细胞外基质的仿生；支架具有高孔隙率和高比表面积的特点,利于细胞的黏附、迁移、生长及分化。
发明内容
本发明的目的是提供一种双导电载药复合神经导管及其制备方法，旨在提高周围神经损伤的修复效果。
上述目的是通过以下技术方案实现的：
本发明的第一个目的是提供一种双导电载药复合神经导管，该导管为中空管状结构，导管内层为含有导电物质二维碳化钛的聚乳酸静电纺丝纤维；导管外层为导电物质聚吡咯涂层，导管中间层为含齐墩果的聚乳酸静电纺丝纤维。
其中，所述导管内层的厚度为0.1-0.3mm，导管外层的厚度为0.08-0.15mm，导管中间层的厚度为0.5-2mm。
本发明的第二个目的是提供一种双导电载药复合神经导管的制备方法，该方法包括以下步骤：
1)用有机溶剂溶解聚乳酸和平均粒径100-1000nm的二维碳化钛，制成聚乳酸浓度5-10％、二维碳化钛浓度0.1-1％的纺丝溶液，进行静电纺丝，得到导电定向静电纺丝纤维；
2)用有机溶剂溶解聚乳酸和齐墩果酸，制成聚乳酸浓度5-10％、齐墩果酸浓度0.05-0.2％的纺丝溶液，将步骤1)制备的导电定向静电纺丝纤维裁剪成小块并包覆在接收器上，用含有齐墩果的纺丝溶液进行静电纺丝，形成载药神经导管；
3)用有机溶剂溶解聚吡咯，制成聚吡咯浓度1-5％的喷涂溶液，均匀喷涂到步骤2)制备的载药神经导管表面，室温干燥后脱模，得双导电载药复合神经导管。
优选地，所述静电纺丝的工艺参数为：接收器转速1000-1500r/min，推注速度为0.1-1mm/min，电压10-15KV，接收距离20-30cm，温度20-30℃，湿度30-50％。
优选地，所述二维碳化钛的平均粒径为300-500nm，在使用前通过研磨使其达到所需的粒径。
优选地，所述纺丝溶液中，聚乳酸的浓度为6-8％。
优选地，所述纺丝溶液中，二维碳化钛的浓度为0.5-0.8％；齐墩果酸的浓度为0.05-0.1％。
根据本发明的一个实施例，其中一种较佳的制备方法如下：
1)导电定向静电纺丝纤维的制备
用二氯甲烷溶解聚乳酸和平均粒径500nm的二维碳化钛，制成聚乳酸浓度8％、二维碳化钛浓度0.8％的纺丝溶液，进行静电纺丝，得到导电定向静电纺丝纤维；
2)载药神经导管的制备
用二氯甲烷溶解聚乳酸和齐墩果酸，制成聚乳酸浓度8％、齐墩果酸浓度0.08％的纺丝溶液，将步骤1)制备的导电定向静电纺丝纤维裁剪成小块并包覆在接收器上，用含有齐墩果的纺丝溶液进行静电纺丝，形成载药神经导管；
3)双导电载药复合神经导管的制备
用乙醇溶解聚吡咯，制成聚吡咯浓度3％的喷涂溶液，均匀喷涂到步骤2)制备的载药神经导管表面，室温干燥后脱模，得双导电载药复合神经导管，
步骤1)、2)中，所述静电纺丝的工艺参数为：接收器转速为1400r/min，推注速度为0.5mm/min，电压12KV，接收距离25cm，温度25℃，湿度40％。
本发明使用聚乳酸为纺丝材料，通过负载二维碳化钛并进行定向纺丝来制备导电定向静电纺丝纤维膜并以此为内层，通过负载齐墩果酸纺丝纤维形成中间层导管，最后采用静电喷涂在神经导管的表面涂覆聚吡咯导电层，最终制备成双导电载药复合神经导管。两种导电物质可以保证导管导电的持续性，纤维的定向排列和药物的释放也可以减轻周围神经损伤导致的炎症，进一步促进受损神经的修复。
神经缺损中巨噬细胞的特定表型对周围神经的再生发挥重要作用。这些活化的巨噬细胞主要分为促炎(M1)和促愈合(M2)两种表型。其中M1型巨噬细胞通过产生高水平的促炎细胞因子来支持炎症，而M2型巨噬细胞通过分泌抗炎细胞因子和生长因子来促进组织修复，这些因子介导细胞增殖、血管生成和基质重塑。研究结果表明，本发明制备的神经导管可显著诱导巨噬细胞(RAW264.7细胞)极化，促进其向M2表型分化，且极化的巨噬细胞在体外具有更好的促进雪旺细胞增殖和迁移的能力，进而促进受损神经元的存活及其轴突的再生。
本发明的有益效果是：
1)本发明使用了两种导电材料，以掺入纺丝和静电喷涂两种方式负载在神经导管上，内外两层都有导电率，极大增加了导管的机械强度和细胞的黏附性，同时也满足了电刺激的需要及导电的连续性，延长了神经再生的进程。
2)本发明使用了齐墩果酸和定向排列的纺丝纤维，已有研究表明，定向排列的纺丝纤维具有促进神经细胞再生的作用，而齐墩果酸则可以通过促巨噬细胞向M2极化来减轻周围神经损伤后导致的炎症反应，发挥与定向排列纺丝纤维的协同作用，进一步促进受损神经元的修复及其轴突的再生。
3)本发明所使用的材料包括聚乳酸、聚吡咯、二维碳化钛等均具有良好的生物相容度及可降解性，且廉价易得，适用于大规模生产。
附图说明
图1为导电定向静电纺丝纤维膜的扫描电镜图。
图2为双导电载药神经导管的外观示意图。
具体实施方式
为了更好的理解本发明，下面结合实施例进一步阐述本发明的内容，但本发明的内容不仅仅局限于下面的实施例。实施例中所使用的单层碳化钛和聚吡咯均为市售产品，分别从中科雷鸣(北京)科技有限公司和湖北诺纳科技有限公司购买获得，也能使用以下方法自制：
导电物质二维碳化钛合成：取0.5g钛碳化铝，加入到1mol/L的氟化氢铵水溶液中，刻蚀铝层，反应5天后，离心洗涤干燥得到多层碳化钛粉末。取0.1g多层碳化钛粉末加入20ml N,N-二甲基甲酰胺中，快速搅拌，降低材料层层间的相互作用力，超声离心洗涤干燥得到单层碳化钛粉末。
导电物质聚吡咯合成：取3.5g十二烷基硫酸钠均匀分散在70ml去离子水中，向其中缓慢滴入1ml吡咯，搅拌均匀后先其中25ml六水合氯化铁水溶液转移到低温反应釜中反应，在-5℃下反应12h后离心洗涤干燥得聚吡咯。
实施例1
双导电载药复合神经导管的制备方法如下：
1)导电定向静电纺丝纤维膜的制备
用7.5g二氯甲烷溶解0.6g聚乳酸，将0.06g二维碳化钛研磨至平均粒径500nm，然后均匀分散于聚乳酸溶液中，制成聚乳酸浓度8％、二维碳化钛浓度0.8％的纺丝溶液，进行静电纺丝，得到导电定向静电纺丝纤维，置于烘箱中50℃干燥后备用。
2)载药神经导管的制备
用12.5g二氯甲烷溶解1g聚乳酸和0.01g齐墩果酸，制成聚乳酸浓度8％、齐墩果酸浓度0.08％的纺丝溶液，将步骤1)制备的导电定向静电纺丝纤维裁剪为5cm×5cm的正方形，缠绕包覆在接收器上，用含有齐墩果的纺丝溶液进行静电纺丝，形成载药神经导管。
3)双导电载药神经导管的制备
将0.3g聚吡咯均匀分散于10ml无水乙醇中，制成聚吡咯浓度3％的喷涂溶液，均匀喷涂到载药神经导管表面，室温干燥后从接收器上脱模，得双导电载药神经导管。
步骤1)、2)中，所述静电纺丝的工艺参数为：接收器转速为1400r/min，推注速度为0.5mm/min，电压12KV，接收距离25cm，温度25℃，湿度40％。
图1为导电定向静电纺丝纤维膜的扫描电镜图，导电纺丝纤维定向排列，直径1-10μm。
图2为双导电载药神经导管的外观结构示意图，所制备的产品为中空管状结构，表面为黑色。内层为含有导电物质二维碳化钛的聚乳酸静电纺丝纤维，厚度约0.2mm；外层为导电物质聚吡咯涂层，厚度约0.1mm；中间层为含齐墩果的聚乳酸静电纺丝纤维，厚度约1mm。
将制备的双导电载药神经导管用四探针电阻率仪测导电率，该导管在生理盐水中放置7周后的导电率仍可达到1.9×10-3S/cm，依然满足最低电刺激10-4S/cm的要求。本发明使用了二维碳化钛和聚吡咯两种导电材料，并通过适当的工艺将其复合，所制备的神经导管导电持续更久，更有利于神经细胞的恢复与再生。
实施例2
双导电载药复合神经导管的制备方法如下：
1)导电定向静电纺丝纤维膜的制备
用二氯甲烷溶解聚乳酸，将二维碳化钛研磨至平均粒径200nm，然后均匀分散于聚乳酸溶液中，制成聚乳酸浓度6％、二维碳化钛浓度1％的纺丝溶液，进行静电纺丝，得到导电定向静电纺丝纤维，置于烘箱中50℃干燥后备用。
2)载药神经导管的制备
用二氯甲烷溶解聚乳酸和齐墩果酸，制成聚乳酸浓度6％、齐墩果酸浓度0.05％的纺丝溶液，将步骤1)制备的导电定向静电纺丝纤维裁剪为5cm×5cm的正方形，缠绕包覆在接收器上，用含有齐墩果的纺丝溶液进行静电纺丝，形成载药神经导管。
3)双导电载药神经导管的制备
将聚吡咯均匀分散于无水乙醇中，制成聚吡咯浓度5％的喷涂溶液，均匀喷涂到载药神经导管表面，室温干燥后从接收器上脱模，得双导电载药神经导管。
步骤1)、2)中，所述静电纺丝的工艺参数为：接收器转速为1200r/min，推注速度为1mm/min，电压10KV，接收距离25cm，温度25℃，湿度40％。
实施例3
双导电载药复合神经导管的制备方法如下：
1)导电定向静电纺丝纤维膜的制备
用二氯甲烷溶解聚乳酸，将二维碳化钛研磨至平均粒径800nm，然后均匀分散于聚乳酸溶液中，制成聚乳酸浓度10％、二维碳化钛浓度0.5％的纺丝溶液，进行静电纺丝，得到导电定向静电纺丝纤维，置于烘箱中50℃干燥后备用。
2)载药神经导管的制备
用二氯甲烷溶解聚乳酸和齐墩果酸，制成聚乳酸浓度10％、齐墩果酸浓度0.12％的纺丝溶液，将步骤1)制备的导电定向静电纺丝纤维裁剪为5cm×5cm的正方形，缠绕包覆在接收器上，用含有齐墩果的纺丝溶液进行静电纺丝，形成载药神经导管。
3)双导电载药神经导管的制备
将聚吡咯均匀分散于无水乙醇中，制成聚吡咯浓度1％的喷涂溶液，均匀喷涂到载药神经导管表面，室温干燥后从接收器上脱模，得双导电载药神经导管。
步骤1)、2)中，所述静电纺丝的工艺参数为：接收器转速为1500r/min，推注速度为0.3mm/min，电压15KV，接收距离25cm，温度25℃，湿度40％。
试验例
试验例1、神经导管对PC12细胞生长的影响
将本发明制备的双导电载药神经导管与PC12细胞共培养并施加电刺激，培养后的第5天进行CCK-8细胞增殖活力检测，具体方法如下：
为了研究电刺激(ES)与神经支架对神经轴突生长的影响，制备双导电神经导管放入孔板中，支架两端穿透铂丝用来连接电刺激装置电极。以1×106个的细胞密度在孔板中接种PC12细胞，每孔填充3mL新鲜培养基，并在37℃下培养24小时以使细胞贴壁，之后每天施加10μA的电流ES处理1h，连续培养5天，隔天换一次新鲜培养液。于第5天进行检测，先在倒置荧光显微镜下观察细胞生长状态，然后向孔板中加入10μLCCK-8，轻轻晃动使其混合均匀，在细胞培养箱培养4小时，取出培养板，弃去上清液，酶标仪上检测其OD值，通过观察各组的OD值可以初步判断神经导管对细胞的作用，OD值越高，说明细胞增殖活力越强。重复试验5次，同时设置空白组和以下对照组：
对照组1：制备静电纺丝纤维膜时未向纺丝溶液中加入二维碳化钛，得到仅有一种导电材料即聚吡咯的单导电载药神经导管。
对照组2：制备载药神经导管后未使用聚吡咯喷涂，室温干燥后直接脱模，得到仅有一种导电材料即二维碳化钛的单导电载药神经导管。
对照组3：步骤2)中未向聚乳酸纺丝液中加入齐墩果酸，得到不载药的双导电神经导管。
对照组1-3中，未予说明的工艺步骤均与实施例1相同。
表1双导电神经导管对PC12细胞的影响(n＝5)
| 分组 | OD(450nm) |
| 空白组 | 1.33±0.34 |
| 实施例1 | 1.92±0.62** |
| 实施例2 | 1.71±0.57* |
| 实施例3 | 1.84±0.61** |
| 对照组1 | 1.48±0.45 |
| 对照组2 | 1.59±0.41* |
| 对照组3 | 1.65±0.50* |
与空白组相比，*P<0.05；**P<0.01
从试验结果可以得出，本发明制备的双导电载药复合神经导管促进了PC12细胞的增殖，与单导电载药神经导管或不载药的双导电神经导管相比，本发明对pc12细胞的增殖效果更好。
试验例2、神经导管对药物释放的影响
将实施例制备的双导电载药神经导管放入pH值为7.4的磷酸盐缓冲盐水(PBS)中，放在摇床中(37℃，70rpm)，并在特定时间收集释放介质。以齐墩果酸标准品制备对照品溶液，在210nm波长下，用HPLC方法测定齐墩果酸的药物释放量。
本发明制备的神经导管，齐墩果酸10天的释放量在25％左右，20天的累积释放量约55％，30天左右接近峰值，累积释放量约80％。本发明将齐墩果酸负载于聚乳酸纺丝纤维中，且位于复合神经导管的中间层，实现了较好的缓释效果。研究表明，齐墩果酸通过促巨噬细胞向M2极化来减轻周围神经损伤后导致的炎症反应，能为神经细胞的再生创造更加有利的外部环境，而缓慢释放的齐墩果酸有利于延长作用时间。
Claims (7)
1.一种双导电载药复合神经导管，其特征在于：为中空管状结构，导管内层为含有导电物质二维碳化钛的聚乳酸静电纺丝纤维；导管外层为导电物质聚吡咯涂层，导管中间层为含齐墩果酸的聚乳酸静电纺丝纤维。
2.如权利要求1所述的双导电载药复合神经导管，其特征在于：所述导管内层的厚度为0.1-0.3mm，导管外层的厚度为0.08-0.15mm，导管中间层的厚度为0.5-2mm。
3.一种制备权利要求1或2所述双导电载药复合神经导管的方法，其特征在于包括以下步骤：
1）用有机溶剂溶解聚乳酸和平均粒径100-1000nm的二维碳化钛，制成聚乳酸浓度5-10％、二维碳化钛浓度0.1-1％的纺丝溶液，进行静电纺丝，得到导电定向静电纺丝纤维；
2）用有机溶剂溶解聚乳酸和齐墩果酸，制成聚乳酸浓度5-10％、齐墩果酸浓度0.05-0.2％的纺丝溶液，将步骤1）制备的导电定向静电纺丝纤维裁剪成小块并包覆在接收器上，用含有齐墩果酸的纺丝溶液进行静电纺丝，形成载药神经导管；
3）用有机溶剂溶解聚吡咯，制成聚吡咯浓度1-5％的喷涂溶液，均匀喷涂到步骤2）制备的载药神经导管表面，室温干燥后脱模，得双导电载药复合神经导管。
4.如权利要求3所述的制备方法，其特征在于，所述静电纺丝的工艺参数为：接收器转速1000-1500r/min，推注速度为0.1-1mm/min，电压10-15KV，接收距离20-30cm，温度20-30℃，湿度30-50%。
5.如权利要求3所述的制备方法，其特征在于，所述二维碳化钛的平均粒径为300-500nm，在使用前通过研磨使其达到所需的粒径。
6.如权利要求3所述的制备方法，其特征在于：所述纺丝溶液中，聚乳酸的浓度为6-8％。
7.如权利要求3所述的制备方法，其特征在于：所述纺丝溶液中，二维碳化钛的浓度为0.5-0.8％；齐墩果酸的浓度为0.05-0.1％。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310179060.3A CN116196472B (zh) | 2023-02-23 | 2023-02-23 | 一种双导电载药复合神经导管及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310179060.3A CN116196472B (zh) | 2023-02-23 | 2023-02-23 | 一种双导电载药复合神经导管及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116196472A CN116196472A (zh) | 2023-06-02 |
| CN116196472B true CN116196472B (zh) | 2024-03-26 |
Family
ID=86518955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310179060.3A Active CN116196472B (zh) | 2023-02-23 | 2023-02-23 | 一种双导电载药复合神经导管及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116196472B (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102026022B1 (ko) * | 2018-04-11 | 2019-09-26 | 연세대학교 산학협력단 | 효과적인 신경 축삭 돌기 재생 연구를 위한 신경 스캐폴드, 이의 제조방법 및 이를 이용한 세포 성장 확인방법 |
| CN112402689A (zh) * | 2020-11-17 | 2021-02-26 | 武汉理工大学 | 一种填充双载药纳米纤维导电神经修复***及其制备方法 |
| CN113559318A (zh) * | 2021-07-05 | 2021-10-29 | 四川大学 | 一种促神经功能恢复的手性导电修复支架及其制备方法 |
| CN114156408A (zh) * | 2021-11-16 | 2022-03-08 | 东华大学 | 基于离子聚电解质的半导体人造神经纤维器件及其制法 |
| CN114848901A (zh) * | 2022-04-22 | 2022-08-05 | 兰州大学 | 一种3d打印的高导电促愈合型多通道神经导管及其制备方法和应用 |
| WO2023001261A1 (zh) * | 2021-07-23 | 2023-01-26 | 北京诺康达医药科技股份有限公司 | 外周神经复合导管及其制备方法与应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130331869A1 (en) * | 2009-10-16 | 2013-12-12 | M. Brett Runge | Conductive polymeric composites of polycaprolactone fumarate and polypyrrole for nerve regeneration |
-
2023
- 2023-02-23 CN CN202310179060.3A patent/CN116196472B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102026022B1 (ko) * | 2018-04-11 | 2019-09-26 | 연세대학교 산학협력단 | 효과적인 신경 축삭 돌기 재생 연구를 위한 신경 스캐폴드, 이의 제조방법 및 이를 이용한 세포 성장 확인방법 |
| CN112402689A (zh) * | 2020-11-17 | 2021-02-26 | 武汉理工大学 | 一种填充双载药纳米纤维导电神经修复***及其制备方法 |
| CN113559318A (zh) * | 2021-07-05 | 2021-10-29 | 四川大学 | 一种促神经功能恢复的手性导电修复支架及其制备方法 |
| WO2023001261A1 (zh) * | 2021-07-23 | 2023-01-26 | 北京诺康达医药科技股份有限公司 | 外周神经复合导管及其制备方法与应用 |
| CN114156408A (zh) * | 2021-11-16 | 2022-03-08 | 东华大学 | 基于离子聚电解质的半导体人造神经纤维器件及其制法 |
| CN114848901A (zh) * | 2022-04-22 | 2022-08-05 | 兰州大学 | 一种3d打印的高导电促愈合型多通道神经导管及其制备方法和应用 |
Non-Patent Citations (3)
| Title |
|---|
| Natural products for regulating macrophages M2 polarization;Xin Jin, et al;Pharmacological Research;20190731;第145卷;1-28 * |
| 周围神经再生聚吡咯/聚乳酸导电神经导管;徐海星等;中国生物材料学会2013年大会;20151127;全文 * |
| 用于神经修复的自组装材料及导电材料的研究;徐海星;博士论文;20080815;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116196472A (zh) | 2023-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Norahan et al. | Electroactive cardiac patch containing reduced graphene oxide with potential antibacterial properties | |
| Ashtari et al. | Electrically conductive nanomaterials for cardiac tissue engineering | |
| Shrestha et al. | Bio-inspired hybrid scaffold of zinc oxide-functionalized multi-wall carbon nanotubes reinforced polyurethane nanofibers for bone tissue engineering | |
| Akrami-Hasan-Kohal et al. | Curcumin-loaded naturally-based nanofibers as active wound dressing mats: Morphology, drug release, cell proliferation, and cell adhesion studies | |
| Abzan et al. | Development of three-dimensional piezoelectric polyvinylidene fluoride-graphene oxide scaffold by non-solvent induced phase separation method for nerve tissue engineering | |
| Bertuoli et al. | Electrospun conducting and biocompatible uniaxial and Core–Shell fibers having poly (lactic acid), poly (ethylene glycol), and polyaniline for cardiac tissue engineering | |
| Ranjbar-Mohammadi et al. | Fabrication of novel nanofiber scaffolds from gum tragacanth/poly (vinyl alcohol) for wound dressing application: in vitro evaluation and antibacterial properties | |
| JP4526851B2 (ja) | 多糖類のナノスケールの繊維および成形体 | |
| Jin et al. | The electrically conductive scaffold as the skeleton of stem cell niche in regenerative medicine | |
| Hosseinzadeh et al. | The nanofibrous PAN-PANi scaffold as an efficient substrate for skeletal muscle differentiation using satellite cells | |
| Hosoyama et al. | Electroconductive materials as biomimetic platforms for tissue regeneration | |
| Unal et al. | Glioblastoma cell adhesion properties through bacterial cellulose nanocrystals in polycaprolactone/gelatin electrospun nanofibers | |
| Aijie et al. | Nanoscaffolds in promoting regeneration of the peripheral nervous system | |
| KR19990067321A (ko) | 전도성 고분자를 이용한 신경자극 방법 및 장치 | |
| Rajasekaran et al. | Role of nanofibers on MSCs fate: Influence of fiber morphologies, compositions and external stimuli | |
| Xu et al. | Chemical crosslinking and biophysical properties of electrospun hyaluronic acid based ultra-thin fibrous membranes | |
| Lee | Electrically conducting polymer-based nanofibrous scaffolds for tissue engineering applications | |
| Tsai et al. | Electrospun chitosan–gelatin–polyvinyl alcohol hybrid nanofibrous mats: Production and characterization | |
| Qian et al. | Functionalization strategies of electrospun nanofibrous scaffolds for nerve tissue engineering | |
| Olyveira et al. | Human dental pulp stem cell behavior using natural nanotolith/bacterial cellulose scaffolds for regenerative medicine | |
| Soltani et al. | Chitosan/graphene and poly (D, L-lactic-co-glycolic acid)/graphene nano-composites for nerve tissue engineering | |
| KR20170089427A (ko) | 보습능 및 피부재생능이 우수한 나노섬유 지지체 및 그 제조방법 | |
| Yi et al. | Conducting polymer-based scaffolds for neuronal tissue engineering | |
| CN116196472B (zh) | 一种双导电载药复合神经导管及其制备方法 | |
| KR20120036217A (ko) | 젤라틴-아파타이트를 함유하는 생체고분자를 이용한 골 조직 재생용 나노섬유의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |